SCHEMBL5332919

SCHEMBL5332919

CN1CCN(c2cc(F)cc3c2OC(C(=O)Nc2ccc(N4C=CCNC4=O)cc2)CC3)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1B P28222 6/20 0.56
▸ KCNH2 Q12809 1/20 0.56
▸ KDM4E B2RXH2 1/20 0.35
▸ HTR1F P30939 1/20 0.34
▸ NFKB1 P19838 6/20 0.34
▸ NFKB2 Q00653 6/20 0.34
▸ RELA Q04206 6/20 0.34
▸ HTR1A P08908 1/20 0.34
▸ HTR1D P28221 1/20 0.34
▸ HTR2A P28223 1/20 0.34
▸ TRPV1 Q8NER1 1/20 0.34
▸ KMT2A Q03164 2/20 0.33
▸ WDR5 P61964 1/20 0.33
▸ RBBP5 Q15291 1/20 0.33
▸ ASH2L Q9UBL3 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK14 Q16539 1/20 0.33
▸ PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5328471 0.89 HTR1B (0.72) HTR1BKCNH2KDM4ENFKB1NFKB2
SCHEMBL5332698 0.88 HTR1B (0.57) HTR1BKCNH2KDM4ENFKB1NFKB2
SCHEMBL4250243 0.86 HTR1B (0.71) HTR1BKCNH2NFKB1NFKB2RELA
SCHEMBL5308402 0.85 HTR1B (0.57) HTR1BKCNH2KDM4ENFKB1NFKB2
SCHEMBL5309051 0.85 HTR1B (0.58) HTR1BKCNH2KDM4EHTR1FNFKB1
SCHEMBL5308451 0.83 HTR1B (0.78) HTR1BKCNH2KDM4EHTR1AHTR1D
SCHEMBL14529770 0.82 HTR1B (0.66) HTR1BKCNH2NFKB1NFKB2RELA
SCHEMBL5308377 0.82 HTR1B (0.57) HTR1BKCNH2KDM4ENFKB1NFKB2
SCHEMBL5308374 0.82 HTR1B (0.59) HTR1BKCNH2KDM4EKMT2AMEN1
SCHEMBL4247598 0.82 HTR1B (0.65) HTR1BKCNH2KDM4EHTR1AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070135442-A1 Chroman compounds ASTRAZENECA AB (SE) 2007-06-14 — — US disclosed
WO-2007053094-A1 CHROMAN COMPOUNDS AS 5 -HTlB ANTAGONISTS ASTRAZENECA AB (SE) 2007-05-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135442-A1 Chroman compounds CYP3A43, CYP2C9, CYP2C8 HTR1B 592/4885KCNH2 1018/4885KDM4E 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback